key: cord-0869473-hklbmy93
authors: Gonçalves, Bruna Tirapelli; Baiocchi, Glauco
title: Telemedicine and cancer research during the COVID‐19 pandemic
date: 2020-10-13
journal: J Surg Oncol
DOI: 10.1002/jso.26254
sha: fbd61beb9b26c3cad0426e0f68f98dfd525e6feb
doc_id: 869473
cord_uid: hklbmy93

nan

(47.8%), and 9 (39.1%) patients, respectively. Although analyzing only a single contact, we found higher compliance rates for telemonitoring compared to overall standard visits (88.5% vs. 58%).

Moreover, telemonitoring was reported by the patients as an opportunity to solve doubts about pandemic and their medical conditions. Only one (4.3%) case described a discomfort in reporting her clinical data by phone call.

Telemedicine emerged as a reliable tool during pandemic not just for patient's consultation but also for follow-up, as clinically excessive visits may increase the exposure and contagious risk for patients and providers. 4 Although not underscoring the importance of physical examination in gynecological cancer, telemedicine emerges as a feasible and reliable method for patients' follow-up in clinical trials even outside the pandemic scenario, increasing the compliance of follow-up and survey application. 1 In a landmark clinical trial of cervical cancer, the compliance rate of at least one QoL survey was 79%, showing the difficulty on this issue. 5 Notably, even during the pandemic, we found a potentially better patients' compliance with telemedicine compared to our previous experience.

Although the main study weakness is the relatively small number of patients, our findings may contribute to literature in this topic. In conclusion, our study suggests that telemedicine may have an important role in monitoring patients included in clinical trials during the COVID-19 pandemic.

The day after COVID-19-Time to rethink oncology clinical research

COVID-19) Dashboard. Situation by country, territory or area

Sentinel Node Mapping in High Risk Endometrial Cancer. ClinicalTrials.gov identifier: NCT 03366051

Safety at the time of the COVID-19 pandemic: how to keep our oncology patients and healthcare workers safe

Quality of life in patients with cervical cancer after open versus minimally invasive radical hysterectomy (LACC): a secondary outcome of a multicentre, randomised, open-label, phase 3, non-inferiority trial